Pharmaceutical Formulation Facilities as Sources of Opioids and Other Pharmaceuticals to Wastewater Treatment Plant Effluents by Phillips, Patrick J. et al.
Pharmaceutical Formulation
Facilities as Sources of Opioids and
Other Pharmaceuticals to
Wastewater Treatment Plant
Effluents
PATRICK J. PHILLIPS,*
,†
STEVEN G. SMITH,
‡ D. W. KOLPIN,
§
STEVEN D. ZAUGG,
‡
HERBERT T. BUXTON,
|
EDWARD T. FURLONG,
‡
KATHLEEN ESPOSITO,
⊥ AND
BEVERLEY STINSON
#
US Geological Survey, 425 Jordan Road, Troy, New York
12180, US Geological Survey, Box 25046, MS415, Lakewood,
Colorado 80225, US Geological Survey, 400 S. Clinton Street,
Iowa City, Iowa 52244, US Geological Survey, Suite 206, 810
Bear Tavern Road, West Trenton, New Jersey 08628, AECOM,
605 Third Avenue, New York, New York 10158, and AECOM,
14504 Greenview Drive, Suite 400, Laurel, Maryland 20708
Received February 2, 2010. Revised manuscript received
April 15, 2010. Accepted May 3, 2010.
Facilities involved in the manufacture of pharmaceutical
products are an under-investigated source of pharmaceuticals
to the environment. Between 2004 and 2009, 35 to 38
efﬂuentsampleswerecollectedfromeachofthreewastewater
treatment plants (WWTPs) in New York and analyzed for
sevenpharmaceuticalsincludingopioidsandmusclerelaxants.
Two WWTPs (NY2 and NY3) receive substantial ﬂows
(>20% of plant ﬂow) from pharmaceutical formulation facilities
(PFF) and one (NY1) receives no PFF ﬂow. Samples of
efﬂuents from 23 WWTPs across the United States were
analyzed once for these pharmaceuticals as part of a national
survey. Maximum pharmaceutical efﬂuent concentrations
forthenationalsurveyandNY1efﬂuentsamplesweregenerally
<1 µg/L. Four pharmaceuticals (methadone, oxycodone,
butalbital, and metaxalone) in samples of NY3 efﬂuent had
medianconcentrationsrangingfrom3.4to>400µg/L.Maximum
concentrations of oxycodone (1700 µg/L) and metaxalone
(3800 µg/L) in samples from NY3 efﬂuent exceeded 1000 µg/L.
Threepharmaceuticals(butalbital,carisoprodol,andoxycodone)
in samples of NY2 efﬂuent had median concentrations
ranging from 2 to 11 µg/L. These ﬁndings suggest that current
manufacturing practices at these PFFs can result in pharma-
ceuticals concentrations from 10 to 1000 times higher than those
typically found in WWTP efﬂuents.
Introduction
Over the past decade, numerous studies have documented
theoccurrenceofpharmaceuticalsinstreams(1-4)andhave
identiﬁed wastewater treatment plants (WWTPs) as a major
source of these compounds to the environment (5, 6).
Improvement in analytical capabilities has revealed an
expanding range of pharmaceuticals in the environment,
includingbenzodiazepines(7,8),barbiturates(9,10),opioids
(7, 10, 11), antidepressants (8, 12), and muscle relaxants
(13, 14). The long-term effects of low-level exposure to
complex mixtures of pharmaceuticals on stream biota are
poorly understood, although a variety of potential adverse
effects have been documented at these low levels, including
acute and chronic damage (15, 16), accumulation in tissues
(12, 17), reproductive damage (18), inhibition of cell pro-
liferation (19), and behavioral changes (20, 21). Continued
research to identify and quantify pharmaceuticals in sus-
ceptible environmental settings and to identify potential
ecological effects in those settings is essential for the future
protection of water quality and ecological health.
The discharges of facilities that manufacture pharma-
ceutical products are an under-investigated source of
pharmaceuticals to the environment, with only limited data
currently available worldwide. Pharmaceutical manufactur-
ing facilities include pharmaceutical production facilities
(PPF),whichproduceactivepharmaceuticalingredients,and
pharmaceuticalformulationfacilities(PFF),whichformulate
and package pharmaceutical products (22). Past studies of
pharmaceutical sources to the environment have focused
onconsumeruseanddisposalandhospitalwaste(14,23,24).
However, a study in India (25) found pharmaceutical
concentrations as high as 31 000 µg/L in a WWTP efﬂuent
that receives substantial discharges from PMFs, and these
dischargeshaveresultedinnearbygroundwaterandsurface
water concentrations as high as 2500 µg/L (26). Similarly,
diclofenec concentrations exceeded 20 µg/L in a Taiwan
WWTP efﬂuent that received PPF discharge (27). These
concentrations are orders of magnitude higher than typical
concentrations reported for WWTP efﬂuents in the U.S. and
Europe (generally <1 µg/L). To our knowledge, no study has
directlymeasuredpharmaceuticalsinaWWTPreceivingPFF
or PPF discharges in the United States or Europe. Modeled
estimates of concentrations of pharmaceuticals in a WWTP
inSwitzerlandreceivingPFFdischargeusingamassbalance
approach ranged from <0.01 to 38 µg/L (22), and research
has suggested that discharges from manufacturing facilities
in Europe may result in observed elevated antiviral con-
centrations in river water (28).
The purpose of this paper is the following:
(1) Present the environmental occurrence of seven
pharmaceuticals(Table1)inefﬂuentsfrom23WWTPsacross
theUnitedStates.Thesepharmaceuticalsrepresentsomeof
the most frequently prescribed medications in the United
States (29), and some (metaxalone, phendimetrazine) have
not been previously included in efﬂuent or stream studies.
(2) Compare the concentrations and mixtures of pharma-
ceuticals in two WWTP efﬂuents that receive discharge from
PFFs with those of one not receiving such PFF discharge and
23 other WWTPs from across the United States.
(3) Compare the limited available information on phar-
maceuticals formulated at the PFFs to the pharmaceuticals
detected in this study, including qualitatively identiﬁed
compounds.
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in waters downstream of three select WWTPs, considering
the source strength of WWTP efﬂuents and dilution by
streamﬂow.
Experimental Section
Site Selection and Sampling. Samples were collected from
26WWTPs,including(1)anetworkof23WWTPsin12states
across the United States serving a wide range of population
sizes (Supporting Information Table S-1), hereafter referred
toasthenationalsurvey,and(2)threeselectWWTPsinNew
York State (sites NY1, NY2, and NY3). More than half of the
WWTPs in the national survey receive discharge from
hospitals (Table S-1); all sites in the national survey were
sampled once between 2006 and 2009, four as 24-h ﬂow
composites, and 19 as grab samples. Grab samples were
generally collected between 8 a.m. and 1 p.m.
BetweenJuly2004andJune2009,35-38efﬂuentsamples
(seeTableS-2)werecollectedfromsitesNY1,NY2,andNY3.
One of these sites (NY1) does not receive PFF or hospital
input. NY2 receives approximately 20% of its ﬂow from a
PFF and also receives ﬂow from a hospital. NY3 receives
approximately 20% of its wastewater inﬂow from another
PFF(TableS-1).Over30streamsampleswerecollectedwithin
afewkmofthecorrespondingoutfallsforthesethreeWWTPs
(Table S-3) using standard width- and depth-integrating
techniques. No tributaries enter the stream between the
efﬂuentdischargeandthestream-samplinglocations.Finally,
16 samples were collected between 2006 and 2009 from a
drinking water reservoir 30 km downstream of site NY2 to
assess the concentrations of pharmaceuticals in water used
for human consumption. Most efﬂuent samples and all
reservoir samples were collected as grab samples, but a few
24-hﬂow-weightedcompositesampleswerecollectedatNY1
(n ) 2), NY2 (n ) 1), and NY3 (n ) 3). The median difference
betweenthe15pairedconcentrationsavailablefromthethree
concurrentgrabandcompositesamplesavailablefromNY3
was 40%, and all of these differences were <70%, indicating
thatconcentrationsinsimplegrabsampleswerewellwithin
an order of magnitude of composite samples. All data
presented in this paper (including blank and replicate data)
are available elsewhere (30).
ChemicalAnalyses.SamplePreparationandAnalysis.The
method of analysis for the seven pharmaceuticals is based
upon a previously described method developed for the
determination of domestic and industrial wastewater com-
pounds (31). Supporting Information pages S-10 through
S-29 describe method development, performance, and
qualitative analysis of additional compounds.
One-litersampleswereﬁlteredthrough0.7-µmglass-ﬁber
ﬁlters prior to solid-phase extraction (SPE), and were
extractedbyvacuumﬁltrationthrough500-mgOASIS-HLB-
SPE cartridges. Sample extracts were analyzed by capillary
gas chromatography/mass spectrometry (GC/MS) operated
underfullscanconditions.Resultswerereportedonlyifthey
met qualitative GC/MS criteria (retention time, mass spec-
trometric ion-abundance ratios, and mass spectra) before
being quantitated based on a 5-8 point calibration curve.
Samples collected after March 2006 included analysis for all
sevenpharmaceuticals;thosecollectedbeforethisdatelacked
analysisofcarisoprodol.Methoddetectionlimits[determined
according to methods speciﬁed in ref 32] ranged from 0.011
to 0.076 µg/L (Table 1).
For samples collected before April 2009, the maximum
calibrationpointsusedforanalysiswere4µg/Lfordiazepam,
400 µg/L for metaxalone, and 40 µg/L for all other pharma-
ceuticals. As it became apparent that many concentrations
exceededtheselevels,adjustmentsweremadetothestandard
operating procedure for the method to ensure accurate
analysis over the extremely wide range of concentrations
encountered. This included extending the upper point of
the calibration curve to 4000 µg/L for metaxalone and 400
µg/L for all other pharmaceuticals after April 2009. Con-
centrationsexceedingthecalibrationcurvebeforeApril2009
were censored to the maximum calibration concentration.
ConcentrationsforsixNY3efﬂuentsamplesquantiﬁedabove
40 or 400 µg/L before April 2009 were determined by either
(1)dilutingsamples,(2)extractinglesseramountsofsample,
or (3) reanalyzing frozen archived samples.
MethodPerformance.Differentspikingexperiments(two
reagent set spike experiments at low and medium concen-
trations, three efﬂuent spike experiments at low, medium,
and high concentrations, and a stream spike experiment at
medium concentrations; see pages S-15 to S-19 in the
Supporting Information) were included to characterize
method performance. Of the 14 reagent set spikes, only the
mean recovery for the low concentration (0.2 µg/L) cariso-
prodol spike (140%) lies outside the 60-130% range, and
only the two oxycodone spikes (low level at 46% and high
levelat34%)haveRSDs(relativestandarddeviations)>30%.
Of the 19 efﬂuent spikes, two mean recoveries-methadone
for the moderate spike (59%) and oxycodone for the low-
level spike (170%)-have mean recoveries outside the
60-130% range. Only one of the 19 efﬂuent spikes, the low
level methadone spike, has an RSD >30% (31%).
Thespikingresultsshowthattheefﬂuentconcentrations
for the seven pharmaceuticals in this study have low bias
and variability. Although the low-level reagent set spikes
indicate that carisoprodol may have a positive bias for low
concentrations, the other reagent spike and efﬂuent spikes
for carisoprodol range from 94 to 113%, suggesting no bias.
Themethadonespikerecoveryfortheefﬂuentspikeatmiddle
range(8µg/L)concentrationsindicatesaslightlowbias(59%),
yet the other two methadone efﬂuent spikes for low (0.2 µg/
L) and high (g90 µg/L) range concentrations (63 and 91%,
respectively) show no bias. The results indicate a positive
TABLE 1. List of Seven Target Pharmaceuticals with Chemical Properties and Method Detection Level
compound CAS No.
a compound class Log Kow
b
water solubility
(mg/L)
b
method detection
limit
c (µg/L)
butalbital 77-26-9 barbiturate 1.87 1700 0.014
carisoprodol 78-44-4 muscle relaxant 2.36 300 0.021
diazepam 439-14-5 benzodiazepine tranquilizer 2.82 50.0 0.012
metaxalone 1665-48-1 muscle relaxant 2.60 90.7 0.011
methadone 76-99-3 opioid 3.93 48.5 0.044
oxycodone 76-42-6 opioid 0.66 4160 0.076
phendimetrazine 634-03-7 amphetamine 1.70 17300 0.021
a This report contains CAS Registry Numbers, which is a Registered Trademark of the American Chemical Society. CAS
recommends the veriﬁcation of the CASRNs through CAS Client Services.
b Chemical properties from online database
http://www.syrres.com/esc/physdemo.htm (viewed January 2008).
c Method detection limits were determined from 10
reagent water samples fortiﬁed at 0.05 µg/L and 7 reagent water samples fortiﬁed at 0.20 µg/L.
VOL. 44, NO. 13, 2010 / ENVIRONMENTAL SCIENCE & TECHNOLOGY 9 4911biasforoxycodoneforlow(0.2µg/L)efﬂuentconcentrations,
yet the two other oxycodone efﬂuent spikes for moderate (8
µg/L) and high (g24 µg/L) concentrations have mean
recoveries of 94 and 70%, respectively. The high RSDs for
reagent set spikes suggest that oxycodone concentrations
may be more variable than other pharmaceuticals in this
study, however the efﬂuent spikes for oxycodone all have
RSDs < 30%.
The stream spike recoveries for butalbital, carisoprodol,
diazepam, and metaxalone were between 60 and 130%, and
RSDswerelessthan30%,indicatinglowbiasandvariability.
Becauseofthelow(32%)andvariable(RSDof48%)recovery
for methadone stream spikes, streamwater data for metha-
done are only reported qualitatively (as percent detection).
The low recoveries for stream spikes for oxycodone and
phendimetrazine (both 57%) suggest that the stream con-
centrations for these two pharmaceuticals may be biased
low. In addition, the RSD for the oxycodone stream spike
was 36%, indicating a higher variability for stream concen-
trations for this pharmaceutical than the others.
QualityControl.Sixty-nineﬁeldblankswerecollectedand
analyzed during the study: 22 collected before March 2006
were analyzed for all of the target pharmaceuticals but
carisoprodol, and the 47 collected after March 2006 were
analyzed for all seven pharmaceuticals. Field blanks were
preparedfromlaboratory-gradeorganic-freewaterandwere
processed and handled using the same methods as WWTP-
efﬂuent and stream samples. Three analytes were detected
in ﬁeld blanks: butalbital (two blanks ranging from 0.045 to
0.051 µg/L), oxycodone (two blanks, ranging from 0.15 to
0.73µg/L),andmetaxalone(sevenblanksrangingfrom0.068
to 1.0 µg/L). Blank detections were associated with efﬂuent
samples containing high pharmaceutical concentrations
(>100 µg/L) and were attributed to the carryover of high
concentrations to later samples in the same sample set.
Concentrations in environmental samples within 10 times
the blank concentrations collected during the same week
were censored to a nondetection. Metaxalone blank con-
taminationalsooccurredin20%ofmethodblanks,therefore
metaxalone concentrations below 3 µg/L (10 times the 90th
percentile of ﬁeld blank concentrations) were censored to a
nondetection.
Analyses of 36 replicate samples yielded 85 paired-
replicate detections of analytes, and 6 unpaired replicate
detections (a detection in only one of the paired samples).
All but one of the unpaired detections occurred for con-
centrations <0.2 µg/L. Median relative percent differences
(RPDs) were similar among analytes, ranging from 3.9% for
metaxalone to 13% for oxycodone. RPDs were somewhat
greater for low concentration comparisons (9.9% for con-
centrations <0.2 µg/L) compared to high concentration
comparisons (4.3% for concentrations >10 µg/L).
Results
National Survey of WWTP Efﬂuent. Five of the seven
pharmaceuticalstestedweredetectedinatleastoneefﬂuent
collectedfromthe23WWTPsincludedinthenationalsurvey
(Figure1).Butalbital(83%)wasthemostfrequentlydetected
compound, followed by oxycodone (56%) and carisoprodol
(43%). Maximum concentrations ranged from 0.1 µg/L.
(diazepam) to 0.31-0.73 µg/L. (butalbital, carisoprodol,
methadone, and oxycodone). Metaxalone and phendime-
trazine were not detected in these samples. The concentra-
tions for most of these pharmaceuticals are similar to
concentrationsofpharmaceuticalsfoundinotherstudiesof
WWTPefﬂuentsintheU.S.andEurope(7-11,14).Thisstudy,
however, provides the ﬁrst data for some of these pharma-
ceuticals in the U.S.
The median total pharmaceutical concentration (equal
to the sum of detected concentrations of all seven analytes
for each sample) for the 14 WWTPs that receive discharge
from a hospital facility (0.32 µg/L) was not signiﬁcantly
different (p > 0.05; Kruskall-Wallace test) from the median
totalpharmaceuticalconcentrationinsamplesfromtheeight
WWTPs without hospital input (0.096 µg/L; see Figure 2A).
However, the WWTPs that received hospital waste had
signiﬁcantly higher daily ﬂows than sites not receiving
hospitalwaste(p<0.05;Kruskall-Wallacetest),complicating
this comparison. Direct measurement of hospital efﬂuents
is necessary to effectively characterize pharmaceutical
contributions from hospitals (24).
Concentrations of Pharmaceuticals in NY1, NY2, and
NY3Efﬂuents,2004-2009.Themediantotalpharmaceutical
concentrationinsamplesofNY1efﬂuent(aWWTPreceiving
neither hospital nor PFF input) was 0.38 µg/L, and thus was
comparabletothoseforsamplesinthenationalsurvey(Figure
2A, B). By contrast, the median total pharmaceutical con-
centration in samples from NY2 efﬂuent (26 µg/L) and NY3
efﬂuent (450 µg/L), both of which receive substantial PFF
discharge,weresigniﬁcantlyhigherthanthatforNY1efﬂuent
(Figure 2B).
Median total pharmaceutical concentrations in samples
of NY2 and NY3 efﬂuents were generally 30 to almost 500
times higher than total pharmaceutical concentrations
typically found in the national efﬂuent survey. None (0 of
161) of the individual pharmaceutical concentrations de-
termined for the national survey were greater than 1 µg/L.
Similarly, only 1.6% (4 of 242) of individual pharmaceutical
concentrations in samples of NY1 efﬂuent exceeded 1 µg/L.
However, 36% (84 of 236) of the individual pharmaceutical
concentrations in samples of NY2 efﬂuent and 61% (155 of
254) of the individual pharmaceutical concentrations in
samples of NY3 efﬂuent exceeded 1 µg/L (Figure 3).
Median concentrations for the ﬁve pharmaceuticals
(butalbital, metaxalone, methadone, oxycodone, and phen-
dimetrazine) most commonly detected in samples of NY3
efﬂuentrangedfrom0.5to>400µg/L;medianconcentrations
for the four pharmaceuticals (butalbital, carisoprodol, di-
azepam, and oxycodone) most commonly detected in
samples of NY2 efﬂuent ranged from 0.74 to 11 µg/L (Figure
3). By contrast, median concentrations for the two phar-
FIGURE 1. Concentrations of seven pharmaceuticals analyzed in
efﬂuent from 23 wastewater treatment plants sampled across
the United States between 2006 and 2009. Box plots depict
range of concentrations, with top whisker equal to 90th
percentile of concentrations, bar at the top of box equal to the
75th percentile, bar at the middle of the box equal to the 50th
percentile, bar at the bottom of the box equal to the 25th
percentile, and bottom whisker equal to the 10th percentile.
Dots above the top of the whisker represent maximum
concentrations, number above boxplot refers to percent of
samples with a positive detection. Dashed line at bottom of
boxplot or whisker denotes method detection limit.
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detectedinsamplesofNY1efﬂuentwere0.10and0.19µg/L,
respectively (Figure 3). Maximum concentrations of oxyc-
odoneandmetaxaloneinsamplesofNY3efﬂuentwere1700
and 3800 µg/L, respectively, and maximum concentrations
of three other pharmaceuticals (butalbital, methadone, and
phendimetrazine) ranged from >40 to >400 µg/L. Two
pharmaceuticals(butalbitalandcarisoprodol)hadmaximum
concentrations >40 µg/L in samples of NY2 efﬂuent. Thus,
theconcentrationsofmanyoftheindividualpharmaceuticals
in samples of NY2 and NY3 efﬂuent were between 10 and
1000 times higher than those found in (1) the NY1 efﬂuent
samples, (2) the samples collected in the national survey of
23 WWTP efﬂuents (including those receiving hospital
discharges), and (3) efﬂuents in other studies (cited above).
Theseconcentrations,however,aresimilartothoseobserved
in a WWTP receiving PPF efﬂuent in India (25).
The efﬂuent samples from NY2 and NY3 contained
complex mixtures of pharmaceuticals. Many of the samples
of NY3 efﬂuent (15 of 38, or 39%) had four or more
pharmaceuticalswithconcentrations>10µg/L,andmanyof
the samples of NY2 efﬂuent (15 of 35, or 43%) had two or
more pharmaceuticals with concentrations >1 µg/L. Con-
centrations of four pharmaceuticals exceeded 40 µg/L in a
sampleofNY3efﬂuentcollectedinFebruary2009(butalbital
110 µg/L, metaxalone 230 µg/L, methadone 41 µg/L, and
oxycodone 1700 µg/L).
IthasbeenhypothesizedthatcurrentGoodManufacturing
PracticeandEfﬂuentEmission(useanddisposal)regulations
of the U.S. Food and Drug Administration (FDA), manu-
facturing efﬂuent discharge and emission regulations of the
U.S. Environmental Protection Agency (EPA), and the inher-
entvalueofactivepharmaceuticalingredientswouldrestrict
the loss of pharmaceutical products from manufacturing
facilities (33). However, the results presented here indicate
thatconcentrationsofpharmaceuticalsforWWTPsreceiving
substantial discharges from a PFF can exceed 1000 µg/L.
Theseconcentrationsaresubstantiallyhigherthanthose(1)
predicted by models based on normal consumer use of
pharmaceuticals (34), (2) modeled for a PFF in Switzerland
(22), and (3) cited as representative of maximum WWTP
efﬂuent concentrations (35). These results demonstrate the
need for environmental data from a variety of sources,
including PFFs, to verify models and other approaches to
estimating source loads and predicting environmental phar-
maceutical concentrations (36).
Relation of Pharmaceutical Concentrations to Produc-
tionData.Completedataonpharmaceuticalsformulatedat
thePFFsdischargingtoWWTPsNY2andNY3arenotavailable
and were estimated based on several sources: (1) direct FDA
identiﬁcation of select pharmaceuticals formulated at these
sites (37), (2) a New York State Report indicating use of two
pharmaceuticals at the PFF discharging to NY3 (38), (3) a
Web site operated by The U.S. National Institutes of Health
(NIH) that provides labels for select pharmaceuticals that
identify the company marketing the pharmaceutical or the
company manufacturing the pharmaceutical (39), and (4)
manufacturers’ Web sites that list the pharmaceuticals
marketed by the owners of the PFFs (40, 41). The ﬁrst two
sources, although the most accurate, include few pharma-
ceuticals. The last two sources can conﬁrm that the owner
ofthePFFmarketsthepharmaceuticalsincludedinthestudy,
but do not necessarily indicate that the pharmaceutical is
produced at a speciﬁc PFF. FDA (37) noted that over 100
products were formulated at the PFF discharging to NY2,
and that the list provided of pharmaceuticals formulated at
both PFFs was not complete. A list of the target pharma-
ceuticals and additional pharmaceuticals qualitatively iden-
tiﬁed in efﬂuent samples from NY2 and NY3 along with
informationonwhethertheyaremanufacturedormarketed
bytheownerofthePFFaregiveninSupportingInformation
Tables S-4 and S-5.
One(methadone)oftheﬁvepharmaceuticalscommonly
detected in NY3 efﬂuent were identiﬁed by the FDA as
formulated at the PFF discharging to NY3 (Table S-5). The
two pharmaceuticals (oxycodone and metaxalone) found in
NY3 efﬂuent at concentrations greater than 1000 µg/L were
notidentiﬁedbytheFDAasformulatedatthePFFdischarging
to NY3. Metaxalone, however, was identiﬁed as formulated
atthissitebybothNewYorkState(38)andtheNIHWebsite
(39).BoththeNIHWebsiteandthemanufacturer’sWebsite
indicate that oxycodone and the other pharmaceuticals
detectedathighconcentrationsatNY3efﬂuentaremarketed
by the corporation operating this PFF (Table S-5; 40). Only
one (oxycodone) of the four pharmaceuticals commonly
detected in NY2 efﬂuent was identiﬁed by the FDA as
formulated at the PFF discharging to NY2 (Table S-4; 37).
The manufacturer’s Web site, however, indicated that
oxycodone and the other three pharmaceuticals (butalbital,
carisoprodol, and diazepam) were marketed by the corpora-
tion operating this PFF (41).
During the course of the study, 19 additional pharma-
ceuticalsorpharmaceuticaldegradatesinsamplesfromNY2
and NY3 efﬂuents were qualitatively identiﬁed using au-
thentic standards (Tables S-4 and S-5). Seven of these
pharmaceuticals were identiﬁed by the FDA as being
formulatedbythePFFsdischargingtothesesites.Inaddition,
14 other pharmaceuticals were identiﬁed by FDA as formu-
lated at these sites, but were not included as target analytes
FIGURE 2. Total concentration of seven pharmaceuticals
detected in wastewater treatment plant (WWTP) efﬂuent
samples for (A) individual samples from 23 WWTPs across the
United States, and (B) multiple samples from WWTPs NY1, NY2,
and NY3. NH ) WWTPs that do not receive discharges from
hospitals. H d WWTPs that receive discharges from hospitals.
Individual concentrations are plotted for NH sites because less
than 12 samples are available for this category. Concentrations
plotted along x-axis (at 0.01 ug/L) denote nondetects. Site NY1
does not receive discharge from a hospital or a pharmaceutical
formulation facility (PFF). Site NY2 receives discharge from a
hospital and approximately 20% of its discharge from a PFF.
Site NY3 receives approximately 20% of its discharge from a
PFF, but does not receive discharge from a hospital. For sites
NY1, NY2, and NY3, only those samples with determinations for
all seven analytes are included in the total concentration
calculation. An explanation of a box plots is given in Figure 1.
Total concentrations for H site type are not signiﬁcantly
different from NH site type for Wilcoxon sum rank test. Total
concentrations for NY3 are signiﬁcantly greater than NY1 and
NY2, and total concentrations for NY2 samples are signiﬁcantly
greater than NY1 samples by Tukey nonparametric test. For
sites NY1, NY2, and NY3, only those samples with
determinations for all seven analytes are included in the total
calculation (samples collected before 2006 did not include
analysis for carisoprodol).
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These results indicate that the pharmaceuticals included in
this study may only represent a fraction of the pharmaceu-
ticals potentially present in the efﬂuent at these sites.
Carisoprodol concentrations in NY2 efﬂuent and corre-
sponding downstream samples decreased after early 2008,
and butalbital concentrations in NY2 efﬂuent and corre-
sponding downstream samples increased after early 2008
(Supporting Information Figure S-1). The limited data from
the drinking water reservoir 30 km downstream from NY2
alsoindicatethatcarisoprodolconcentrationsdecreasedand
butalbital concentrations increased since early 2008 (Figure
S-1). NY3 efﬂuent concentrations for methadone and metax-
alone were consistently high in samples collected between
2004 and 2009, while oxycodone and butalbital concentra-
tions varied temporally (Figure S-2). These data provide
evidence that the emission of pharmaceuticals from PFFs is
notshort-term(ontheorderof1day)assuggestedpreviously
(22). Temporal variations in pharmaceutical concentrations
in efﬂuent of WWTPs with PMFs may relate to operational
changes in the facilities, or seasonal differences in removal
attheWWTP.Theserelationscannotbedeterminedwithout
information on pharmaceutical use, production, and other
operational practices in such facilities. The lack of a single
reliable source of data on pharmaceuticals used at PFFs
hampers the ability to fully identify the suite of pharma-
ceuticals that may be present in WWTP efﬂuents receiving
these discharges as well as downstream waters that may
include water used for human consumption.
ConcentrationsofPharmaceuticalsDownstreamofNY1,
NY2, and NY3 Efﬂuents. Stream pharmaceutical concentra-
tions frequently exceeded 1 µg/L in samples collected
downstreamfromtheNY2discharge(SupportingInformation
Figure S-3). Over half of the stream samples collected below
the NY2 discharge had two or more pharmaceuticals with
concentrationsgreaterthan1µg/L.Thepharmaceuticalswith
thehighestconcentrationsinstreamsamplesbelowtheNY2
discharge (Figure S-3) correspond to the pharmaceuticals
withthehighestconcentrationsinsamplesfromNY2efﬂuent
(Figure 3). Pharmaceutical concentrations in the stream
below the NY2 discharge are generally higher than those
typically found in WWTP efﬂuent samples (Figure 1) due to
a combination of high efﬂuent concentrations and limited
dilutionbythereceivingstream(TableS-3;FigureS-4).These
results suggest that future research should be conducted to
determinewhetherthesepharmaceuticalconcentrationsare
affecting aquatic biota.
Pharmaceutical concentrations in samples downstream
of NY1 discharge rarely exceeded 0.1 µg/L (Figure S-3),
reﬂecting the lower pharmaceutical concentrations in NY1
efﬂuentsamplescomparedtoNY2efﬂuentsamples.Although
concentrations in samples collected from the NY3 efﬂuent
often exceeded 10 µg/L (Figure 3) only two pharmaceuticals
(metaxalone and oxycodone) exceeded 1 µg/L in samples
collecteddownstreamoftheNY3discharge(FigureS-3).The
lower concentrations of pharmaceuticals in samples down-
streamofNY3comparedtosamplesdownstreamofNY2can
be attributed to the high amount of dilution (0.17% of ﬂow
derived from efﬂuent downstream of NY3, compared to
15%-24% for the other two sites; see Table S-3) at this site.
Assessing PMFs as Sources of Pharmaceuticals. This
study demonstrates that while an ever broader range of
pharmaceuticals are commonly found in WWTP efﬂuents
and streams below these discharges (generally at <1 µg/L)
speciﬁcsourcessuchasPFFscanleadtocircumstanceswhere
pharmaceuticalconcentrationsare10-1000foldhigherthan
generallymeasuredinWWTPefﬂuentsampleswithoutsuch
input.Thus,becausecurrentmodelingapproachesarebased
on only consumer use and disposal and do not take into
account inputs from PMFs they may signiﬁcantly underes-
FIGURE 3. Concentrations of seven pharmaceuticals analyzed in samples of efﬂuent from wastewater treatment plants (WWTPs)
NY1, NY2, and NY3 during 2004-2009. Site NY1 does not receive discharge from a hospital or a pharmaceutical formulation facility
(PFF). Site NY2 receives discharge from a hospital and approximately 20% of its discharge from a PFF. Site NY3 receives
approximately 20% of its discharge from a PFF, but does not receive discharge from a hospital. Box plots depict range of
concentrations, and are explained in Figure 1. Number above boxplot refers to percent detection. Numbers of samples for each site
are indicated next to the site name. Twenty four samples were analyzed for carisoprodol at each site. Concentrations of methadone,
oxycodone, carisoprodol, and phendimetrazine above 40 µg/L and metaxalone above 400 µg/L were frequently censored because
many of these concentrations were above the maximum point on the calibration curve. Concentrations quantiﬁed above these levels
plotted as open circles were below the maximum point on the calibration curve. Boxplots for pharmaceuticals with censoring in
more than 25% of the samples (including methadone, oxycodone, and metaxalone in NY3 samples) were denoted by a boxplot
truncated at the upper end with a bar. Dashed line at bottom of boxplot or whisker denotes method detection limit.
4914 9 ENVIRONMENTAL SCIENCE & TECHNOLOGY / VOL. 44, NO. 13, 2010timate potential maximum pharmaceutical concentrations
from WWTP efﬂuents. Furthermore, toxicological assess-
mentsbasedonsubppblevelsofpharmaceuticalsinstreams
are unlikely to adequately account for the potential deleteri-
ous effects of both high individual chemical concentrations
andchemicalmixturesresultingfromPMFdischarges.Access
to additional information on pharmaceutical use and dis-
charges by PMFs is needed to accurately predict the
concentrations and ecological effects of these under-
investigated sources. Until such information is available, a
forensic approach similar to the one used in this research
will be needed to accurately determine the complex range
of pharmaceuticals originating from such PMF discharges.
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